Paulson & CO. Inc. Makes New $361.15 Million Investment in Bausch Health Cos Inc. $BHC

Paulson & CO. Inc. acquired a new position in Bausch Health Cos Inc. (NYSE:BHC) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 73,255,869 shares of the company’s stock, valued at approximately $361,151,000. Bausch Health Cos makes up 14.0% of Paulson & CO. Inc.’s portfolio, making the stock its 4th largest holding. Paulson & CO. Inc. owned approximately 0.20% of Bausch Health Cos as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in BHC. Royal Bank of Canada lifted its holdings in shares of Bausch Health Cos by 24.9% during the 1st quarter. Royal Bank of Canada now owns 11,363,498 shares of the company’s stock valued at $61,362,000 after acquiring an additional 2,262,894 shares in the last quarter. MFN Partners Management LP acquired a new stake in Bausch Health Cos in the 2nd quarter valued at $29,580,000,000. Goldman Sachs Group Inc. increased its holdings in Bausch Health Cos by 65.7% in the 4th quarter. Goldman Sachs Group Inc. now owns 5,143,641 shares of the company’s stock valued at $35,748,000 after purchasing an additional 2,038,813 shares in the last quarter. Norges Bank purchased a new position in Bausch Health Cos in the fourth quarter valued at about $25,592,000. Finally, Dimensional Fund Advisors LP raised its position in Bausch Health Cos by 10.8% in the first quarter. Dimensional Fund Advisors LP now owns 3,604,818 shares of the company’s stock valued at $19,456,000 after purchasing an additional 350,823 shares during the period. Hedge funds and other institutional investors own 78.65% of the company’s stock.

Insider Buying and Selling at Bausch Health Cos

In other news, insider Aimee J. Lenar sold 36,827 shares of Bausch Health Cos stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $7.03, for a total transaction of $258,893.81. Following the sale, the insider directly owned 334,853 shares of the company’s stock, valued at approximately $2,354,016.59. The trade was a 9.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 20.67% of the stock is owned by corporate insiders.

Bausch Health Cos Price Performance

BHC opened at $6.74 on Wednesday. The company has a fifty day simple moving average of $5.43 and a 200 day simple moving average of $5.48. The firm has a market cap of $2.52 billion, a price-to-earnings ratio of -2.28 and a beta of 0.38. Bausch Health Cos Inc. has a twelve month low of $4.33 and a twelve month high of $8.00. The company has a current ratio of 1.44, a quick ratio of 1.08 and a debt-to-equity ratio of 54.68.

Bausch Health Cos (NYSE:BHC) last issued its quarterly earnings data on Wednesday, July 29th. The company reported $1.26 EPS for the quarter, topping analysts’ consensus estimates of $0.96 by $0.30. Bausch Health Cos had a negative net margin of 10.12% and a negative return on equity of 561.95%. The firm had revenue of $2.83 billion for the quarter, compared to analyst estimates of $2.59 billion. Equities research analysts expect that Bausch Health Cos Inc. will post 4.35 EPS for the current fiscal year.

Analyst Ratings Changes

BHC has been the subject of several analyst reports. Wall Street Zen raised Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 1st. Zacks Research upgraded Bausch Health Cos from a “strong sell” rating to a “hold” rating in a report on Thursday, August 20th. Jefferies Financial Group raised Bausch Health Cos to a “hold” rating in a research report on Wednesday, July 22nd. Finally, Weiss Ratings upgraded Bausch Health Cos from a “sell (d-)” rating to a “sell (d)” rating in a report on Friday, July 31st. Six analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Reduce” and a consensus price target of $8.00.

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.